We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Blood Test Predicts Neuroendocrine Tumor Response to Radiopharmaceutical Therapy

By LabMedica International staff writers
Posted on 11 Apr 2023

Biomarkers have been employed to forecast treatment outcomes for breast, prostate, and other types of cancer, although no objective methods currently exist for predicting the success of radiopharmaceutical therapy for neuroendocrine tumors. More...

Now, a new study has revealed that a simple blood test can supply doctors with crucial information to ascertain if peptide receptor radionuclide therapy (PRRT) is likely to be effective in patients with neuroendocrine cancer. The blood-based biomarker PPQ can accurately predict PRRT responsiveness in 96% of patients, and changes in another biomarker, NETest, correlate with PRRT response in 90% of cases.

Previously, a group of nuclear medicine physicians at Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA) had introduced the blood-based biomarkers PPQ and NETest as indicators for the success of PRRT treatment. In this new study, the team aimed to validate the significance of PPQ and NETest in predicting and monitoring PRRT response. The new study included 67 patients with somatostatin receptor-positive gastroenteropancreatic and lung neuroendocrine tumors, all of whom had metastatic disease and prior treatments. The participants submitted blood samples before each PRRT cycle and during follow-up. PPQ was scored as either positive (likely to respond) or negative (unlikely to respond), while NETest was measured on a scale of zero to 100, with 20 being the upper limit of normality.

Of the 67 patients, 40 were classified as PPQ+ and 39 of them (98%) responded to PRRT. Among the 27 PPQ- patients, 25 experienced disease progression despite PRRT. The overall predictive accuracy of PPQ was 96%. Prior to PRRT therapy, all patients exhibited elevated NETest levels. In PRRT responders, baseline NETest levels were 67, decreasing by 37% after treatment. For non-responders, baseline NETest levels were 44, which rose by 76% during follow-up. NETest's accuracy in determining PRRT response was 90%.

“The results of this study demonstrate that not all tumors are created equal; some are more prone to respond to PRRT, and some are less susceptible to radiopharmaceutical therapy,” said Lisa Bodei, MD, PhD, nuclear medicine physician at Memorial Sloan Kettering Cancer Center. “This is the reason why our research is important: to understand from the start which patients will require an intensified treatment plan and which patients, instead, can benefit from a lighter regimen will tremendously improve their management.”

Related Links:
MSK


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.